New drug combo shows promise in Hard-to-Treat breast cancer

NCT ID NCT02390427

Completed Disease control Sponsor: Otto Metzger, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called taselisib combined with standard anti-HER2 therapies in 68 people with advanced HER2+ breast cancer. The goal was to find the safest dose and see if the combination could shrink tumors or slow the disease. While not a cure, the approach aims to better control cancer that has spread or come back.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2 + BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER RECURRENT BREAST CANCER

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.